Press releaseGlobe Newswire
Dyne Therapeutics
DYN · NASDAQ
$16.27+$1.04 (+6.83%)TodayMarket closed ·
Prev close $15.23
Latest news
- NewsVandana Singh
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling
- NewsAvi Kapoor
Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings
- NewsAvi Kapoor
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
- Press releaseGlobe Newswire
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings
- Press releaseGlobe Newswire
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting
- Press releaseGlobe Newswire
Dyne Therapeutics to Participate in Upcoming Investor Conferences
- Press releaseGlobe Newswire
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- Press releaseGlobe Newswire
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
- NewsAvi Kapoor
Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
- NewsTanya Rawat
Dyne Therapeutics Stock Tumbles After Hours: Here's Why
- Press releaseGlobe Newswire
Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
- Press releaseGlobe Newswire
Dyne Therapeutics Appoints Barry Greene to Board of Directors
- Press releaseGlobe Newswire
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
- Press releaseGlobe Newswire
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)
- Press releaseGlobe Newswire
Dyne Therapeutics to Participate in Upcoming Investor Conferences
- Press releaseGlobe Newswire
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
- NewsAvi Kapoor
Nio, Zevra Therapeutics, Vertex Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
- NewsVandana Singh
Sarepta CEO To Jump Ship After 'Tumultuous' Year
- Press releaseGlobe Newswire
Dyne Therapeutics to Participate in Upcoming Investor Conferences
- Press releaseGlobe Newswire
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
- Press releaseGlobe Newswire
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
- NewsAvi Kapoor
Daktronics, Photronics, Dave & Buster's Entertainment, GE Vernova And Other Big Stocks Moving Higher On Wednesday
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- NewsVandana Singh
Dyne's Duchenne Drug Shows Strong Muscle And Function Improvements
- NewsAvi Kapoor
Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana And Other Big Stocks Moving Higher On Monday
- Press releaseGlobe Newswire
Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
- Press releaseGlobe Newswire
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
- NewsAvi Kapoor
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday
- Press releaseGlobe Newswire
Dyne Therapeutics to Present at Upcoming Investor Conferences
- Press releaseGlobe Newswire
Dyne Therapeutics to Present at Upcoming Investor Conferences
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsOn Behalf of Investors of Dyne Therapeutics, Inc. - DYN
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
- NewsAvi Kapoor
These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
- NewsAvi Kapoor
Why Thumzup Media Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.